Use of the novel INNO-LiPA line probe assay for detection of hepatitis B virus variants that confer resistance to entecavir therapy.
A line probe assay (INNO-LiPA DR, version 3) for the detection of hepatitis B virus mutations that confer resistance to entecavir therapy was evaluated. The INNO-LiPA DR assay is a highly sensitive assay that is easily applicable for the detection and monitoring of entecavir resistance-conferring mutations and is more sensitive than sequencing for the detection of mixed sequences.
Jardi
Rosendo
R
Departments of Biochemistry, Hospital Universitario Vall d'Hebron, Barcelona, Spain. rjardi@vhebron.net
Rodriguez-Frias
Francisco
F
Tabernero
David
D
Homs
Maria
M
Schaper
Melanie
M
Esteban
Rafael
R
Buti
Maria
M
D000998:Antiviral Agents / Q000494:pharmacology*; D004279:DNA, Viral / Q000235:genetics; D005838:Genotype; D006147:Guanine / Q000031:analogs & derivatives* / Q000494:pharmacology; D006515:Hepatitis B virus / Q000187:drug effects / Q000235:genetics* / Q000302:isolation & purification*; D006801:Humans; D025202:Molecular Diagnostic Techniques / Q000379:methods*; D020125:Mutation, Missense; D009693:Nucleic Acid Hybridization / Q000379:methods*; D012680:Sensitivity and Specificity
D000998:Antiviral Agents; D004279:DNA, Viral; C413685:entecavir; D006147:Guanine